Literature DB >> 8027948

Drug toxicokinetics: scope and limitations that arise from species differences in pharmacodynamic and carcinogenic responses.

A Monro1.   

Abstract

Toxicokinetics describes the concentration and time course of a xenobiotic in the circulation under the conditions of a toxicology study. However, the fundamental challenge to the toxicologist, of extrapolating the findings in animals to a risk assessment in humans, requires knowledge and understanding of both the pharmacokinetics and pharmacodynamic responses in each species. This paper exemplifies situations where measurement of plasma concentrations may provide information useful in the design and interpretation of the toxicity observed in a given species; it also illustrates how intrinsic interspecies differences in pharmacodynamic response limit the extrapolation of toxicity data across species. The special case of the multistage cumulative phenomenon of carcinogenicity, with the implications of daily dose, duration of dosing, and species differences in response, is also discussed.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8027948     DOI: 10.1007/bf02353409

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  33 in total

Review 1.  Design of toxicokinetic studies.

Authors:  D A Smith; M J Humphrey; C Charuel
Journal:  Xenobiotica       Date:  1990-11       Impact factor: 1.908

Review 2.  Scientific concepts, value, and significance of chemical carcinogenesis studies.

Authors:  J Huff; J Haseman; D Rall
Journal:  Annu Rev Pharmacol Toxicol       Date:  1991       Impact factor: 13.820

3.  alpha 1-Adrenoceptors in the mammalian brain: similar pharmacology but different distribution in rodents and primates.

Authors:  J M Palacios; D Hoyer; R Cortés
Journal:  Brain Res       Date:  1987-09-01       Impact factor: 3.252

Review 4.  Too many rodent carcinogens: mitogenesis increases mutagenesis.

Authors:  B N Ames; L S Gold
Journal:  Science       Date:  1990-08-31       Impact factor: 47.728

Review 5.  Diseases and drug protein binding.

Authors:  J P Tillement; F Lhoste; J F Giudicelli
Journal:  Clin Pharmacokinet       Date:  1978 Mar-Apr       Impact factor: 6.447

Review 6.  Drug binding to human alpha-1-acid glycoprotein in health and disease.

Authors:  J M Kremer; J Wilting; L H Janssen
Journal:  Pharmacol Rev       Date:  1988-03       Impact factor: 25.468

7.  Correlation of hepatocellular proliferation with hepatocarcinogenicity induced by the mutagenic noncarcinogen:carcinogen pair--2,6- and 2,4-diaminotoluene.

Authors:  M L Cunningham; J Foley; R R Maronpot; H B Matthews
Journal:  Toxicol Appl Pharmacol       Date:  1991-03-01       Impact factor: 4.219

8.  Cellular and plasma adriamycin concentrations in long-term infusion therapy of leukemia patients.

Authors:  P A Speth; P C Linssen; J B Boezeman; H M Wessels; C Haanen
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

9.  Interspecies extrapolation in carcinogenesis: prediction between rats and mice.

Authors:  L S Gold; L Bernstein; R Magaw; T H Slone
Journal:  Environ Health Perspect       Date:  1989-05       Impact factor: 9.031

Review 10.  Predicting the carcinogenicity of chemicals in humans from rodent bioassay data.

Authors:  G Goodman; R Wilson
Journal:  Environ Health Perspect       Date:  1991-08       Impact factor: 9.031

View more
  2 in total

1.  Toxicity of LY303366, an echinocandin antifungal, in mice pretreated with glucocorticoids.

Authors:  K V Clemons; R A Sobel; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

Review 2.  The use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drug development.

Authors:  D K Walker
Journal:  Br J Clin Pharmacol       Date:  2004-12       Impact factor: 4.335

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.